Czech National Bank Has $17.27 Million Position in Cencora, Inc. $COR

Czech National Bank boosted its holdings in Cencora, Inc. (NYSE:COR) by 3.8% during the fourth quarter, HoldingsChannel.com reports. The fund owned 51,124 shares of the company’s stock after purchasing an additional 1,884 shares during the period. Czech National Bank’s holdings in Cencora were worth $17,267,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Norges Bank bought a new stake in shares of Cencora in the 2nd quarter valued at approximately $695,215,000. Marshall Wace LLP lifted its position in shares of Cencora by 518.9% during the 3rd quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock worth $623,534,000 after buying an additional 1,672,762 shares during the period. Mizuho Markets Americas LLC lifted its position in shares of Cencora by 116.4% during the 3rd quarter. Mizuho Markets Americas LLC now owns 212,800 shares of the company’s stock worth $66,506,000 after buying an additional 1,511,906 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Cencora by 528.9% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company’s stock valued at $461,250,000 after buying an additional 1,241,186 shares in the last quarter. Finally, Viking Global Investors LP boosted its stake in Cencora by 95.0% in the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after buying an additional 1,013,913 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Trading Down 2.2%

Shares of COR opened at $318.00 on Friday. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. The company has a market cap of $61.86 billion, a price-to-earnings ratio of 38.22, a PEG ratio of 1.51 and a beta of 0.68. The stock has a fifty day moving average price of $352.91 and a two-hundred day moving average price of $340.41. Cencora, Inc. has a 52-week low of $267.40 and a 52-week high of $377.54.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, topping the consensus estimate of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The company had revenue of $85.93 billion for the quarter, compared to analysts’ expectations of $86.12 billion. During the same quarter in the prior year, the business earned $3.73 earnings per share. The business’s revenue for the quarter was up 5.5% on a year-over-year basis. Analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were issued a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, February 13th. This represents a $2.40 dividend on an annualized basis and a yield of 0.8%. Cencora’s dividend payout ratio is currently 28.85%.

Wall Street Analysts Forecast Growth

COR has been the subject of several recent analyst reports. Robert W. Baird set a $415.00 price objective on Cencora in a research note on Tuesday, January 13th. Jefferies Financial Group upgraded shares of Cencora from an “underperform” rating to a “buy” rating in a research note on Thursday, January 22nd. Evercore reaffirmed an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. Wall Street Zen cut shares of Cencora from a “buy” rating to a “hold” rating in a research report on Friday, November 28th. Finally, Wells Fargo & Company lifted their price target on shares of Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a report on Tuesday, February 10th. Twelve research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $403.17.

Insiders Place Their Bets

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of the business’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total value of $1,807,704.08. Following the completion of the transaction, the chief executive officer directly owned 66,726 shares of the company’s stock, valued at approximately $23,669,713.98. The trade was a 7.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.38% of the company’s stock.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.